Shanghai, China--Recently, the first time registration in Kazakhstan of Dongguan Kewei Medical Instrument Co., Ltd.'s ("Dongguan Kewei") independently researched, developed and produced occluder series products was approved, including Atrial Septal Defect Occluder (ASD Occluder) and Conveying System, Ductus Arteriosus Occluder (PDA Occluder) and Conveying System, Ventricle Septal Defect Occluder (VSD Occluder) and Conveying System.
Dongguan Kewei ASD Occluder and Conveying System, PDA Occluder and Conveying System, VSD Occluder and Conveying System, can be applied to congenital atrial septal defect, interventional treatment of patent ductus arteriosus and ventricular septal defect. Through a conveying pipe, a crack resistance fluid plugging net rack is arranged in the lesion, effectively blocking the abnormal blood flow, enabling tissue defect finally being able to be repaired and reconstructed. Compared with the traditional surgery, the products will cause fewer traumas, less damage without tracheal intubation anesthesia, less pain, and shorter hospitalization time.
Previously, ASD Occluder, PDA Occluder, occluder with conveying system and VSD Occluder have won the CFDA registration certificate, and all occluder series products have entered in market. In addition, some of the occluder series products' registration in India and Russia had been approved. This time's approval of registration in Kazakhstan symbolized that Dongguan Kewei occluder products will officially enter the Kazakhstan market, laying the foundation to further explore the international market, and will bring health and good news for more overseas patients with congenital heart disease.